Mark Stejbach
Director/Board Member presso INDIVIOR PLC
Patrimonio netto: 271 431 $ in data 31/03/2024
Posizioni attive di Mark Stejbach
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| INDIVIOR PLC | Director/Board Member | 24/03/2021 | - |
| Independent Dir/Board Member | 24/03/2021 | - |
Storia della carriera di Mark Stejbach
Precedenti posizioni note di Mark Stejbach
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| FLEXION THERAPEUTICS, INC. | Director/Board Member | 13/09/2016 | 19/11/2021 |
| Independent Dir/Board Member | 13/09/2016 | 19/11/2021 | |
| ALKERMES PLC | Corporate Officer/Principal | 05/03/2012 | 01/10/2018 |
| TENGION, INC. | Public Communications Contact | 21/10/2010 | 01/01/2012 |
| Corporate Officer/Principal | 19/01/2010 | 01/07/2011 | |
| Sales & Marketing | 01/08/2008 | 19/01/2010 | |
Commonwealth National Fund, Inc.
 Commonwealth National Fund, Inc. Financial ConglomeratesFinance Commonwealth National Fund, Inc. functions as an investment fund. The private company is based in Stuart. | Director/Board Member | 01/01/2003 | 01/01/2011 |
| MERCK & CO., INC. | Corporate Officer/Principal | 01/01/1987 | 01/07/2008 |
Biogen MA, Inc.
 Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/01/1997 | 01/01/1997 |
Formazione di Mark Stejbach
| Virginia Polytechnic Institute & State University | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Statistiche
Distribuzione geografica
| Stati Uniti | 9 |
| Irlanda | 2 |
Posizioni
| Corporate Officer/Principal | 4 |
| Director/Board Member | 3 |
| Independent Dir/Board Member | 2 |
Settori
| Health Technology | 7 |
| Consumer Services | 3 |
| Finance | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 4 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| TENGION, INC. | Health Technology |
| INDIVIOR PLC | Health Technology |
| ALKERMES PLC | Health Technology |
| Aziende private | 3 |
|---|---|
Biogen MA, Inc.
Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Health Technology |
Flexion Therapeutics, Inc.
 Flexion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA. | Health Technology |
Commonwealth National Fund, Inc.
Commonwealth National Fund, Inc. Financial ConglomeratesFinance Commonwealth National Fund, Inc. functions as an investment fund. The private company is based in Stuart. | Finance |
- Borsa valori
- Insiders
- Mark Stejbach
- Esperienza
